The biotech Gilead Sciences has been the best-performing healthcare stock in the S&P 500 by far over the past 12 months. Its ...

Gilead Sciences said on Monday a late-stage study showed that its drug Trodelvy used in combination with Merck's ...

Gilead Sciences' Q1 2025 earnings reveal challenges in oncology and Veklury sales, while HIV therapies remain strong. See why ...

Gilead’s HIV product sales, which make up the bulk of its revenue, increased 6% YoY to $4.6 billion, but fell 16% ...

In the first phase 3 trial to show the superiority of a TROP2-targeted antibody-drug conjugate and an immunotherapy agent in ...

Jacquie Ross; Senior Vice President - Treasury, Investor Relations; Gilead Sciences Inc. Daniel O'Day; Chairman, Chief Executive Officer; Gilead Sciences Inc. Johann ...

Gilead Sciences (NasdaqGS:GILD) recently announced positive results from the Phase 3 ASCENT-04/KEYNOTE-D19 study, ...

Gilead Sciences on Thursday reported a first-quarter profit, but revenue was flat, as higher sales of drugs for HIV and liver ...

Despite steep budget and staffing cuts at the FDA in recent weeks and other headwinds, Gilead CEO Daniel O’Day assured investors that the pharma’s plans and preparations for lenacapavir’s launch ...

Combining Trodelvy with Keytruda and pushing it into the frontline setting could “potentially double” the ADC’s market in ...

The study enrolled patients with a PD-L1 combined positive score (CPS) of 10 or more, matching Keytruda's label in first-line ...

Gilead Sciences said a combination of its cancer drug Trodelvy and Merck’s Keytruda delayed the growth of tumors in women ...